Latest News
Initiator Pharma secures two European patents for pudafensine
19 August 2026 - Danish clinical-stage pharmaceutical company Initiator Pharma A/S (FN STO:INIT) announced on Wednesday that it has secured two new European patents for its lead drug candidate pudafensine, strengthening protection for the compound in...
Aqua Medical treats second type 2 diabetes patient in IDE trial of investigational PIMA procedure
19 August 2026 - Aqua Medical Inc, a clinical-stage medical technology company advancing Endoscopic Metabolic Restoration, announced on Tuesday the treatment of the first West Coast patient (second overall in the US) in the company's FDA-approve...
Resivant Medical reports first patient cases with Cutiva PLUS Skin Closure System
19 August 2026 - Resivant Medical announced on Tuesday the first patient uses of its Cutiva PLUS Skin Closure System, marking the first use of its proprietary Cutiva siliconised adhesive platform.This represents the first clinical use of a new cyanoa...
Andelyn Biosciences to develop and manufacture gene therapy AAV9-GM2 for Queen's University to treat GM2 gangliosidoses
19 August 2026 - Andelyn Biosciences Inc, a cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), announced on Tuesday that it has partnered with Queen's University to develop and manufacture AAV9-GM2, a gene therapy ...
Piramal Pharma acquires controlling stake in Yapan Bio
19 August 2026 - Indian pharmaceutical company Piramal Pharma Ltd (PPL) (NSE:PPLPHARMA) (BSE:543635) announced on Tuesday that it has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based CDMO specia...